Cluster 98: pd checkpoint inhibitor immune ctla anti received inhibitors treatment prior 
Cluster 243: pd anti agent received prior therapy treatment merck participated pembrolizumab 
Cluster 439: pd prior therapy treatment inhibitor anti ctla received patients pathway 
Cluster 945: anti ctla adverse pd effects immune weeks dose ctcae met 
Cluster 1113: pd durvalumab including inhibitor previous tremelimumab ctla treatment anti pdl 
Cluster 1533: anti pd ctla prior checkpoint pdl cd antibody immune antibodies 
Cluster 2451: checkpoint immune inhibitor inhibitors prior therapy treatment blockade immunotherapy therapies 
